Stem Cell Therapeutics Corp. is a biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system (CNS) disorders. SCT’s primary program, NTx-265, is a therapeutic regimen of two drugs, human Chorionic Gonadotropin (hCG) and Erythropoietin (EPO), targeting the treatment of stroke. Stem Cell Therapeutics Inc. is the Company’s wholly owned subsidiary.